Developing a multi-center clinical data mart of ACEI and ARB for real-world evidence (RWE)
Abstract Background Randomized controlled trials can be expensive and time-consuming, leading to medical researchers utilizing real-world evidence (RWE) based on already-collected data. We aimed to conduct various RWE studies on angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II rece...
Main Authors: | Hun-Sung Kim, Sue Hyun Lee, Tong Min Kim, Ju Han Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-12-01
|
Series: | Clinical Hypertension |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40885-018-0103-7 |
Similar Items
-
Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
by: Wenjun Wang, et al.
Published: (2021-01-01) -
Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
by: Hee-Sung Kim, et al.
Published: (2021-02-01) -
Consequences of continuing renin angiotensin aldosterone system antagonists in the preoperative period: a systematic review and meta-analysis
by: Qiong Ling, et al.
Published: (2018-02-01) -
ACEIs and ARBs and Their Correlation with COVID-19: A Review
by: Yehualashet AS, et al.
Published: (2020-09-01) -
Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome
by: Yue Zhang, et al.
Published: (2020-04-01)